BCL2 and lymphoma: Navitoclax is another identified senolytic that eliminates senescent cells primarily through targeting the Bcl-2 family of anti-apoptotic proteins including Bcl-2 and Bcl-xl (86) and has undergone phase II clinical trials for lymphoid cancers.